AbbVie Inc.

AbbVie Inc. announced preliminary results for the third quarter of 2026, expecting acquired IPR&D and milestones expense of $216 million, which will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.11. The company updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.76 - $13.96 and its third-quarter 2026 adjusted diluted EPS guidance to $3.73 - $3.77, reflecting this expense. AbbVie noted that acquired IPR&D and milestones expense is not typically forecasted due to the uncertainty of future transactions.

AbbVie Inc. has entered into an underwriting agreement to issue and sell $10 billion aggregate principal amount of senior notes. The offering includes a mix of floating rate and fixed-rate notes with maturities ranging from 2028 to 2066. The net proceeds, estimated at approximately $9.93 billion, are intended to fund a portion of the cash payment for the acquisition of Apogee Therapeutics, Inc. and for other general corporate purposes, including potential debt repayment.

AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, expanding its pipeline in inflammatory conditions. This strategic move accompanies strong second-quarter financial results, with net revenues increasing by 10.2% to $16.99 billion and net earnings attributable to AbbVie Inc. soaring by 285.2% to $3.61 billion. The company also reported significant licensing activities and robust operating cash flow for the first half of 2026.

AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, significantly deepening its immunology portfolio. The company reported strong second-quarter 2026 financial results, with diluted GAAP EPS increasing 290.4% to $2.03 and adjusted diluted EPS rising 22.9% to $3.65. Net revenues grew 10.2% to $16.990 billion, driven by robust performance in its immunology and neuroscience segments. AbbVie also updated its full-year 2026 adjusted diluted EPS guidance to $13.87 - $14.07, reflecting the dilutive impact of the Apogee acquisition, and announced several key product approvals.

AbbVie Inc. announced preliminary second-quarter 2026 results are expected to include a $291 million pre-tax acquired IPR&D and milestones expense. This expense will unfavorably impact both GAAP and non-GAAP diluted earnings per share by $0.17. Consequently, the company has updated its Q2 2026 adjusted diluted EPS guidance to $3.57 - $3.61 and its full-year 2026 adjusted diluted EPS guidance to $13.91 - $14.11, reflecting the impact of this expense.

AbbVie Inc. announced a definitive agreement to acquire Apogee Therapeutics, Inc. for approximately $10.9 billion in an all-cash transaction, paying $135.11 per share. This acquisition aims to deepen AbbVie's immunology portfolio by adding clinical-stage candidates for inflammatory and immunological diseases, including Apogee's lead asset, zumilokibart (APG777), for atopic dermatitis. The transaction is expected to close in the third quarter of 2026 and become accretive to AbbVie's adjusted diluted earnings per share beginning in 2032.

AbbVie reported mixed first-quarter 2026 results with net revenues increasing 12.4% to $15.002 billion, while net earnings attributable to AbbVie Inc. decreased 46.0% to $695 million, and diluted EPS fell 45.8% to $0.39. The decline in profitability was primarily driven by a significant increase in acquired IPR&D and milestones, including a $650 million upfront payment for a license agreement with RemeGen. Despite this, cash flows from operating activities saw a substantial increase to $3.829 billion.

AbbVie Inc., in collaboration with adMare BioInnovations, has awarded the AbbVie Biotechnology Innovators Award to RIME Therapeutics, a Montreal-based startup. This award aims to foster innovation and growth in Quebec's life sciences sector. RIME Therapeutics, founded in 2025, is developing a peptide-based drug discovery platform targeting protein-protein interactions for inflammation and immune disorders. The prize includes one year of free lab and office space, shared services at adMare Innovation Centre, and mentorship from AbbVie's commercial and scientific leaders, supporting RIME's research in areas aligned with AbbVie's therapeutic focus.

AbbVie, in partnership with adMare BioInnovations, recognized RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award. This award aims to foster innovation and support growth in Quebec’s life sciences sector. RIME Therapeutics, founded in 2025, is a Montreal-based startup developing a peptide-based drug discovery platform for inflammation and immunology. The award provides RIME with one year of laboratory and office space at the adMare Innovation Centre, access to shared equipment, and mentorship from AbbVie's scientific and business leaders.

AbbVie Inc. reported strong first-quarter 2026 financial results, with net revenues reaching $15.002 billion, a 12.4% increase, and adjusted diluted EPS growing 7.7% to $2.65. The company exceeded expectations and raised its full-year 2026 adjusted diluted EPS guidance to $14.08 - $14.28. Key growth drivers like Skyrizi, Rinvoq, and the Neuroscience portfolio delivered robust performance, while the company also announced a new FDA approval for Venclexta and submitted applications for Skyrizi and Rinvoq for new indications, though it received a CRL for trenibotulinumtoxinE due to manufacturing process inquiries.